207 related articles for article (PubMed ID: 27600285)
1. Endothelial lipase genetic polymorphisms and the lipid-lowering response in patients with coronary artery disease on rosuvastatin.
Cai G; Zhang B; Shi G; Weng W; Yang L; Xue S
Lipids Health Dis; 2016 Sep; 15(1):148. PubMed ID: 27600285
[TBL] [Abstract][Full Text] [Related]
2. Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin.
Wei KK; Zhang LR
Clin Drug Investig; 2015 Sep; 35(9):583-91. PubMed ID: 26293521
[TBL] [Abstract][Full Text] [Related]
3. Associations of Rs3744841 and Rs3744843 Polymorphisms in Endothelial Lipase Gene with Risk of Coronary Artery Disease and Lipid Levels in a Chinese Population.
Cai G; Zhang B; Ma C; Shi G; Weng W; Xue S
PLoS One; 2016; 11(9):e0162727. PubMed ID: 27612170
[TBL] [Abstract][Full Text] [Related]
4. Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
Kawashiri MA; Yamagishi M; Sakamoto T; Takayama T; Hiro T; Daida H; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
Cardiovasc Ther; 2013 Dec; 31(6):335-43. PubMed ID: 23409830
[TBL] [Abstract][Full Text] [Related]
5. The analysis of the lipid levels in patients with coronary artery disease after percutaneous coronary intervention: a one-year follow-up observational study.
Qiu W; Chen J; Huang X; Guo J
Lipids Health Dis; 2020 Jul; 19(1):163. PubMed ID: 32631347
[TBL] [Abstract][Full Text] [Related]
6. Treatment Trends, Effectiveness, and Safety of Statins on Lipid Goal Attainment in Chinese Percutaneous Coronary Intervention Patients: a Multicenter, Retrospective Cohort Study.
Chen Y; Li D; Jing J; Yan H; Liu J; Shen Z; James S; Varenhorst C
Clin Ther; 2017 Sep; 39(9):1827-1839.e1. PubMed ID: 28807393
[TBL] [Abstract][Full Text] [Related]
7. [ESTIMATING THE EFFECTIVENESS OF HYPOLIPIDEMIC THERAPY WITH ROSUVASTATIN IN PATIENTS WITH CORONARY HEART DISEASE DEPENDING ON THE GENOTYPE OF LIPOPROTEIN LIPASE].
Zvyagina MV; Mal GS; Bushueva OY; Alymenko MA; Bykanova MA; Letova IM; Gribovskaya IA; Churnosov MI; Solodilova MA; Polonikov AV
Eksp Klin Farmakol; 2016; 79(1):15-9. PubMed ID: 27159952
[TBL] [Abstract][Full Text] [Related]
8. SCARB1 single nucleotide polymorphism (rs5888) is associated with serum lipid profile and myocardial infarction in an age- and gender-dependent manner.
Stanislovaitiene D; Lesauskaite V; Zaliuniene D; Smalinskiene A; Gustiene O; Zaliaduonyte-Peksiene D; Tamosiunas A; Luksiene D; Petkeviciene J; Zaliunas R
Lipids Health Dis; 2013 Mar; 12():24. PubMed ID: 23510561
[TBL] [Abstract][Full Text] [Related]
9. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction.
Aydin MU; Aygul N; Altunkeser BB; Unlu A; Taner A
Atherosclerosis; 2015 Apr; 239(2):439-43. PubMed ID: 25697576
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.
Altunkeser BB; Tuncez A; Ozturk B; Tezcan H; Ates MS; Yilmaz C; Yalcin MU; Aygul N; Demir K
Coron Artery Dis; 2019 Jun; 30(4):285-290. PubMed ID: 30741744
[TBL] [Abstract][Full Text] [Related]
12. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
13. [Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation].
Polenova NV; Vaulin NA; Masenko VP; Iavelov IS; Gratsianskiĭ NA
Kardiologiia; 2009; 49(2):9-14. PubMed ID: 19254210
[TBL] [Abstract][Full Text] [Related]
14. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
[TBL] [Abstract][Full Text] [Related]
15. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
Takayama T; Hiro T; Yamagishi M; Daida H; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
Circ J; 2009 Nov; 73(11):2110-7. PubMed ID: 19801853
[TBL] [Abstract][Full Text] [Related]
16. [EFFICIENCY OF CONCOMITANT USE OF POLICOSANOL AND ROSUVASTATIN IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE AND MODERATE HEPATIC DYSFUNCTION].
Solomenchuk TM; Vosukh V; Bedzay A; Koval VG; Chepka IM; Trotsko VV
Lik Sprava; 2015; (7-8):29-37. PubMed ID: 27491147
[TBL] [Abstract][Full Text] [Related]
17. CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy.
Lin J; Zhang Y; Zhou H; Wang X; Wang W
Clin Lab; 2015; 61(9):1317-24. PubMed ID: 26554252
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a generic rosuvastatin in a real-world setting: prospective, observational clinical study in Lebanese patients.
Betto M; Fares J; Saliba N; Ballout H
Ann Saudi Med; 2017; 37(5):366-374. PubMed ID: 28988251
[TBL] [Abstract][Full Text] [Related]
20. Gender specific effect of CETP rs708272 polymorphism on lipid and atherogenic index of plasma levels but not on the risk of coronary artery disease: A case-control study.
Cai G; Shi G; Huang Z
Medicine (Baltimore); 2018 Dec; 97(49):e13514. PubMed ID: 30544452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
